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Abstract
Background: Extensive drug resistance of Acinetobacter baumannii is a serious problem in the clinical setting. It is
therefore important to find active antibiotic combinations that could be effective in the treatment of infections
caused by this problematic ‘superbug’. In this study, we analyzed the in vitro activities of three colistin-based
combinations and a minocycline-based combination against clinically isolated extensive drug resistant Acinetobacter
baumannii (XDR-AB) strains.
Methods: Fourteen XDR-AB clinical isolates were collected. The clonotypes were determined by polymerase chain
reaction-based fingerprinting. Susceptibility testing was carried out according to the standards of the Clinical and
Laboratory Standards Institute. Activities of drug combinations were investigated against four selected strains and
analyzed by mean survival time over 12 hours (MST12 h) in a time-kill study.
Results: The time-kill studies indicated that the minimum inhibitory concentration (MIC) of colistin (0.5 or 0.25 μg/
mL) completely killed all strains at 2 to 4 hours, but 0.5×MIC colistin showed no bactericidal activity. Meropenem (8
μg/mL), minocycline (1 μg/mL) or rifampicin (0.06 μg/mL) did not show bactericidal activity. However,
combinations of colistin at 0.5×MIC (0.25 or 0.125 μg/mL) with each of the above were synergistic and shown
bactericidal activities against all test isolates. A combination of meropenem (16 μg/mL) with minocycline (0.5×MIC,
4o r2μg/mL) was synergitic to all test isolates, but neither showed bactericidal activity alone. The MST12 h values
of drug combinations (either colistin- or minocycline-based combinations) were significantly shorter than those of
the single drugs (p < 0.01).
Conclusions: This study indicates that combinations of colistin/meropenem, colistin/rifampicin, colistin/minocycline
and minocycline/meropenem are synergistic in vitro against XDR-AB strains.
Background
Nosocomial infections caused by drug-resistant Acineto-
bacter baumannii are a major global problem [1].
Recent data from the Chinese Network for Bacterial-
resistance Surveillance demonstrated that the suscept-
ibility of A. baumannii to carbapenems has decreased to
below 50%, and almost 17% of these isolates are resis-
tant to all antimicrobial agents that are routinely used
in clinical practice [2]. Unfortunately, no new antibiotics
will be available for extensive drug resistant (XDR)
gram-negative pathogens including A. baumannii for at
least a decade [3]. These data highlight the importance
and urgency of finding antibiotic combinations that are
effective in the treatment of infections caused by this
problematic “superbug”.
“Old” antibiotics, such as colistin [4] and minocy-
cline [5], are generally active against A. baumannii
strains. Colistin was withdrawn from general clinical
use in the late 1970s because of potential nephrotoxi-
city and neurotoxicity, but now it is increasingly
used worldwide as the last-line therapy against A.
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when combined with some other antibiotics with dif-
ferent modes of action such as carbapenems, rifampi-
cin and ceftazidime [9-13]. Minocycline is a second-
line antibiotic for a number of common bacterial infec-
tions in the clinical setting. Recent studies have indi-
cated that minocycline is a promising drug for the
treatment of A. baumannii infections [5,14]. Further-
more, it can enhance the activity of colistin against
multidrug-resistant A. baumannii isolates [15].
In order to find the combinations that would achieve
complete killing or are bactericidal against XDR-AB iso-
lates, we examined the activities of colistin- and minocy-
cline-based combinations, including colistin/meropenem,
colistin/rifampicin, colistin/minocycline and minocy-
cline/meropenem, against XDR-AB isolates from
patients in the intensive care unit (ICU) of Huashan
Hospital, a 1,400-bed hospital in eastern China.
Methods
Strains and antibiotics
Fourteen XDR-AB strains (resistant to all antimicrobial
agents but one or two) [16] were isolated from patients
admitted to the ICU of Huashan Hospital between Janu-
ary 2009 and March 2010. All these strains were identi-
fied with the API 20NE system (BioMérieux, Marcy
l’Etoile, France). Clonotypes of the strains were deter-
mined by polymerase chain reaction (PCR)-based finger-
printing with primers of ERIC-1 and 2 [17]; the PCR
conditions were as follows: 94°C for 2 min, followed by
40 cycles of 94°C for 1 min, 26°C for 1 min, and 72°C
for 2 min, with a final extension at 72°C for 5 min.
Colistin sulfate (Lot: 30327-200305; 22106 units/mg),
meropenem (Lot: 130506-200702; purity: 87%) and
rifampicin (Lot: 130496-200702; purity: 98%) were
obtained from the National Institute for the Control of
Pharmaceutical and Biological Products of China
(Shanghai, China). Minocycline hydrochloride (Lot:
2000131970/C; purity: 84%) was purchased from Wyeth
Inc. (Madison, NJ, USA). Stock solutions of colistin,
meropenem, rifampicin and minocycline were prepared
with sterile distilled water and kept at -80°C for a maxi-
mum of 2 months before use.
Susceptibility testing
Minimum inhibitory concentrations (MICs) of colistin,
minocycline, rifampicin and meropenem against the
clinical isolates were tested using the broth microdilu-
tion method according to the Clinical and Laboratory
Standards Institute) protocol [18]. Briefly, serial 2-fold
dilutions of an antibacterial agent in cation-adjusted
Mueller-Hinton broth (CaMHB) were prepared in a 96-
well microplate with an inoculum of approximately
5×10
5 cfu/mL. After 24-hour incubation at 35°C in
ambient air, the lowest concentration with no visible
bacterial growth was defined as the MIC. Escherichia
coli ATCC25922 was used as a quality control strain.
The experiments were repeated on 2 different days.
Static time-kill studies
Four strains from different colonotypes (A. baumannii
09-95, 09-1769, 09-2092 and 10-548) were selected for
the time-kill study. Two sets of time-kill studies were
conducted for each strain. In the first set, the colistin
concentration was fixed at 0.5×MIC (0.25 or 0.125 μg/
mL) and each of the other agents was combined with
colistin from high to low concentrations as follows: mer-
openem, 16, 8 and 4 μg/mL; minocycline, 2, 1 and 0.5
μg/mL; and rifampicin, 0.25, 0.125 and 0.06 μg/mL. In
the second set, minocycline concentrations were fixed at
0.5×MIC (4 or 2 μg/mL), and combined with merope-
nem at concentrations of 16 and 8 μg/mL. A growth
control was included in both sets.
An overnight culture was diluted with prewarmed
CaMHB to about 1×10
5 cfu/mL and further incubated at
35°C for 2 hours. Then the medium was divided into a ser-
ies of tubes containing different concentrations of drugs. A
growth control was included. All tubes were incubated in
a shaking incubator (150 rpm) at 35°C. Samples were
taken at 0, 2, 4, 6, 8, 10, 12 and 24 hours and viable bac-
teria were counted on Mueller-Hinton agar (MHA) plates.
The plates were incubated for 18 hours at 35°C, and then
the number of colonies formed was counted. The theoreti-
cal lower limit of quantification was 10 cfu/mL. Bacterici-
dal activity and synergy were defined as ≥ 3 log10 decrease
or ≥ 2 log10 decrease, respectively, in cfu/mL between the
combination and its most active antibiotic alone [19].
Statistical and mathematical analysis
The bactericidal effects of each drug or drug combina-
tion were quantified by calculation of the mean survival
time over 12 h (MST12 h) as previously described [20]:
MST12h =A U M C 0−12h/AUC0−12h
where AUC0-12 h was the area under the time-kill
curve over 0-12 hours, AUMC0-12 h was the area under
the time-kill curve multiplied by the time of sampling in
hours from 0 to 12. Both AUMC0-12 h and AUC0-12 h
were calculated using the linear trapezoidal method.
The analysis of variance (ANOVA) and post hoc analy-
sis were performed to compare the differences between
drug treatments and strains on MST12 h using SPSS sta-
tistical software (SPSS Inc., USA).
Results
The PCR fingerprints demonstrated that the strains
belonged to four clonotypes termed clonotype I, II, III
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meropenem and rifampicin are summarized in Table 1.
All isolates were resistant to meropenem but susceptible
to colistin and minocycline. The MICs of rifampicin
ranged from 4 to 16 μg/mL.
In the time-kill study, no viable cells were detected at
2 to 4 hours in the presence of 1×MIC colistin, and
regrowth was not observed at 24 hours (data not
shown). When the concentration of colistin was
0.5×MIC, the growth of isolates 09-1769 and 10-548
was markedly reduced (Figure 1B and 1D), but the
growth of isolates 09-95 and 09-2092 was only slightly
inhibited compared with the controls (Figure 1A and
1C). An important phenomenon was observed in that
complete killing of all strains was achieved within 2-6
hours when high concentrations of meropenem (16 μg/
mL), minocycline (2 μg/mL) or rifampicin (0.25 μg/mL)
were applied in combination with 0.5×MIC colistin.
When combined with colistin, the lowest concentrations
of minocycline, meropenem and rifampicin presenting a
s y n e r g i s t i ce f f e c tw e r ei d e n t ified for different strains
(Figure 1A, B, C and 1D). For meropenem, 4 μg/mL (i.
e., 1/8-1/32 MIC) was sufficient to present a synergistic
effect with colistin against three strains (not isolate 09-
1769) which represent 92% of the total strains. Similarly,
a minocycline concentration as low as 1 μg/mL (i.e., 1/
4-1/8 MIC) also showed synergy with colistin against all
four isolates. The lowest concentration of rifampicin of
0.06 μg/mL also exhibited a synergistic effect with colis-
tin (no combination of rifampicin at a concentration of
less than 0.06 μg/mL with colistin was included in pre-
sent work).
In the time-kill study with minocycline and merope-
nem alone, the growth of all isolates was inhibited by
0.5×MIC minocycline, but not affected by 16 μg/mL
meropenem alone (Figure 2). Interestingly, synergistic
activity was observed when meropenem was combined
with minocycline. A combination of 16 μg/mL merope-
nem with 0.5×MIC minocycline exhibited bactericidal
activities against all strains at 12 h (Figure 2). Isolate 09-
95 showed susceptibility to this combination with 8 μg/
mL meropenem (data not shown).
The mean survival times of each XDR-AB strain
under different drug treatments are shown in Figure 3.
The data indicated that MST12 h values of colistin- or
minocycline-based combinations were significantly
shorter than that of each drug alone. On average, the
MST12 h values of colistin-based drug combinations
were 3.1 hours shorter than any constituent drug alone
(Figure 3A) (p < 0.01). The MST12 h value of the mino-
cycline/meropenem combination was 1.6 hours shorter
than that of minocycline or meropenem alone (Figure
3B) (p < 0.01).
Discussion
Colistin is unavailable in China, so data are limited
here regarding colistin in the treatment of infections
caused by multidrug-resistant gram-negative bacteria.
T h e1 4X D R - A Bs t r a i n su s e di nt h i ss t u d yw e r ei s o -
l a t e df r o mp a t i e n t si nt h eI C Ui nH u a s h a nH o s p i t a l ,
where there is a high incidence of severe infections
and a major presence of XDR-AB. We demonstrated
that colistin was active against all the strains at a
lower MIC (MIC90 =0 . 5μg/mL) than in other reports
[21]. This may arise from the fact that colistin has not
yet been approved for clinical use in China. The results
of the study were in accordance with previous reports
that colistin/meropenem [9], colistin/rifampicin [10]
Table 1 Acinetobacter baumannii isolates in this study and their MICs
Isolates Infection Sample Clonotype COL (μg/mL) MEM (μg/mL) MINO (μg/mL) RFP (μg/mL)
09-95 VAP Sputum I 0.25 32 4 4
09-154 VAP Sputum I 0.25 16 4 8
09-1769 VAP Sputum II 0.5 64 8 4
09-1782 VAP Sputum I 0.5 16 4 8
09-2092 VAP Sputum I 0.25 128 8 4
09-2221 VAP Sputum I 0.5 64 4 4
09-2902 CB Sputum III 0.5 16 4 4
10-39 CB Sputum I 0.5 64 2 8
10-161 CB Sputum I 0.25 64 2 4
10-415 II CSF I 0.5 64 2 4
10-533 VAP Sputum I 0.25 16 4 8
10-548 HAP Sputum IV 0.5 64 4 16
10-584 VAP Sputum IV 0.5 64 4 8
10-617 CB Sputum IV 0.5 32 2 8
MIC = minimum inhibitory concentration, VAP = ventilator-associated pneumonia, HAP = hospital-acquired pneumonia, CB = colonized bacteria, II = intracranial
infection, CSF = cerebrospinal fluid, COL = colistin (breakpoint = 2 μg/mL), MEM = meropenem (breakpoint = 16 μg/mL), MINO = minocycline (breakpoint = 16
μg/mL), RFP = rifampicin (no breakpoint is available).
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gistic against these strains.
It was considered that colistin should be combined
with other drugs for lower dose-related toxicity, and
recent research has suggested that it is necessary to
combine colistin with another antibiotic to obtain a
pharmacological effect. The most frequently used form
of colistin is colistin methanesulfonate (CMS), which is
a prodrug of colistin without activity [22]. In vivo,
CMS is hydrolyzed to produce the active colistin.
Pharmacokinetic studies have indicated that the
recommended intravenous dose of CMS will present a
stable level of colistin in plasma of 1-4 μg/mL [23],
which should have activity against most A. baumannii
strains (the MIC is 0.5-1 μg/mL). However, if protein-
binding is considered [24], the concentration of free
drug is likely to be reduced to 0.3-1.2 μg/mL, i.e., the
concentration of colistin is under the MIC in many
cases, which may result in treatment failure and
increase the risk of drug resistance. To, combine it
Figure 1 Time-kill curves of each antibiotic alone and in combination with colistin. (A) Isolate 09-95; (B) isolate 09-1769; (C) isolate 09-2092;
(D) isolate 10-548. Dashed line (Log cfu/mL = 1) was the lower limit reference line.
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mL) or rifampicin (≥ 0.06 μg/mL) may achieve bacteri-
cidal effects according to our results. Further observa-
tions are warranted in light of these data.
As in some recent reports [5,14,15], our study also
demonstrated that minocycline is generally active
against A. baumannii. Here, the MIC of minocycline for
the 14 strains was 4 μg/mL. Because of dose-dependent
gastrointestinal and vestibular function disorders [25]
and the risk of drug resistance, minocycline alone is
generally considered unfavorable for the treatment of
XDR-AB, but it may have promising effects in combina-
tion with other antibiotics. In addition to the colistin/
minocycline combination, our results also showed that
minocycline combined with meropenem was effective
against XDR-AB isolates. Our findings point to a possi-
ble option for treatment of XDR-AB infections when
colistin or CMS is unavailable.
Conclusion
Our research indicates that combinations such as colis-
tin/meropenem, colistin/rifampicin and colistin/minocy-
cline are synergistic in vitro against XDR-AB strains.
The minocycline/meropenem combination may be an
alternative option for treatment of infections caused by
XDR A. baumannii when colistin is unavailable.
Figure 2 Time-kill curves of the combinations of minocycline and meropenem. (A) Isolate 09-95; (B) isolate 09-1769; (C) isolate 09-2092; (D)
isolate 10-548. Dashed line (Log cfu/mL = 1) was the lower limit reference line.
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